Cargando…
A Review on the Use of the HPV Vaccine in the Prevention of Cervical Cancer
The main risk factor for invasive cervical carcinoma is persistent infection by the high-risk human papillomavirus (HPV). HPV is the most prevalent sexually transmitted infection (STI) and has been linked to 15 different cancers. Cervical cancer is one of the most frequent cancers among women, parti...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529156/ https://www.ncbi.nlm.nih.gov/pubmed/36211088 http://dx.doi.org/10.7759/cureus.28710 |
_version_ | 1784801443500261376 |
---|---|
author | Pathak, Pranav Pajai, Sandhya Kesharwani, Himanshi |
author_facet | Pathak, Pranav Pajai, Sandhya Kesharwani, Himanshi |
author_sort | Pathak, Pranav |
collection | PubMed |
description | The main risk factor for invasive cervical carcinoma is persistent infection by the high-risk human papillomavirus (HPV). HPV is the most prevalent sexually transmitted infection (STI) and has been linked to 15 different cancers. Cervical cancer is one of the most frequent cancers among women, particularly in resource-limited countries. Cervical cancer is an HPV disease with the highest worldwide burden in resource-limited nations. With improved medical care and nationwide screening programmes, the mortality rate from cervical cancer has decreased in the past 40 years. Many developing nations have been shown to have inadequate knowledge and health-seeking practices, making proper awareness and immunisation programmes necessary. The best strategy to reduce the incidence of cervical cancer is through the administration of HPV vaccines along with routine cervical screening. The HPV vaccine is crucial for public health. Vaccinations against all HPV subtypes, namely, bivalent, quadrivalent, and nonavalent, are available. Financial issues are the main barrier to HPV vaccination. The framework for behavioural and social drivers of vaccination, which includes practical concerns, motivation, social processes, thoughts, and feelings, is widely used to uncover important aspects linked with HPV vaccination. The burden of cervical cancer due to HPV and the advantages of HPV vaccination are summarised in this review article. |
format | Online Article Text |
id | pubmed-9529156 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-95291562022-10-06 A Review on the Use of the HPV Vaccine in the Prevention of Cervical Cancer Pathak, Pranav Pajai, Sandhya Kesharwani, Himanshi Cureus Obstetrics/Gynecology The main risk factor for invasive cervical carcinoma is persistent infection by the high-risk human papillomavirus (HPV). HPV is the most prevalent sexually transmitted infection (STI) and has been linked to 15 different cancers. Cervical cancer is one of the most frequent cancers among women, particularly in resource-limited countries. Cervical cancer is an HPV disease with the highest worldwide burden in resource-limited nations. With improved medical care and nationwide screening programmes, the mortality rate from cervical cancer has decreased in the past 40 years. Many developing nations have been shown to have inadequate knowledge and health-seeking practices, making proper awareness and immunisation programmes necessary. The best strategy to reduce the incidence of cervical cancer is through the administration of HPV vaccines along with routine cervical screening. The HPV vaccine is crucial for public health. Vaccinations against all HPV subtypes, namely, bivalent, quadrivalent, and nonavalent, are available. Financial issues are the main barrier to HPV vaccination. The framework for behavioural and social drivers of vaccination, which includes practical concerns, motivation, social processes, thoughts, and feelings, is widely used to uncover important aspects linked with HPV vaccination. The burden of cervical cancer due to HPV and the advantages of HPV vaccination are summarised in this review article. Cureus 2022-09-02 /pmc/articles/PMC9529156/ /pubmed/36211088 http://dx.doi.org/10.7759/cureus.28710 Text en Copyright © 2022, Pathak et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Obstetrics/Gynecology Pathak, Pranav Pajai, Sandhya Kesharwani, Himanshi A Review on the Use of the HPV Vaccine in the Prevention of Cervical Cancer |
title | A Review on the Use of the HPV Vaccine in the Prevention of Cervical Cancer |
title_full | A Review on the Use of the HPV Vaccine in the Prevention of Cervical Cancer |
title_fullStr | A Review on the Use of the HPV Vaccine in the Prevention of Cervical Cancer |
title_full_unstemmed | A Review on the Use of the HPV Vaccine in the Prevention of Cervical Cancer |
title_short | A Review on the Use of the HPV Vaccine in the Prevention of Cervical Cancer |
title_sort | review on the use of the hpv vaccine in the prevention of cervical cancer |
topic | Obstetrics/Gynecology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529156/ https://www.ncbi.nlm.nih.gov/pubmed/36211088 http://dx.doi.org/10.7759/cureus.28710 |
work_keys_str_mv | AT pathakpranav areviewontheuseofthehpvvaccineinthepreventionofcervicalcancer AT pajaisandhya areviewontheuseofthehpvvaccineinthepreventionofcervicalcancer AT kesharwanihimanshi areviewontheuseofthehpvvaccineinthepreventionofcervicalcancer AT pathakpranav reviewontheuseofthehpvvaccineinthepreventionofcervicalcancer AT pajaisandhya reviewontheuseofthehpvvaccineinthepreventionofcervicalcancer AT kesharwanihimanshi reviewontheuseofthehpvvaccineinthepreventionofcervicalcancer |